Are the current guidelines for the acceptance of generic low molecular weight heparins adequate?

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 4, 2003, Pages 269-272

  Fareed, J ^a   Bick, Rodger L ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CUTENOX; ENOXAPARIN; GENERIC DRUG; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN;

BIOEQUIVALENCE; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; PATENT; PRACTICE GUIDELINE; PRIORITY JOURNAL;

DRUGS, GENERIC; GUIDELINES; HEPARIN, LOW-MOLECULAR-WEIGHT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0242523135     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900402     Document Type: Editorial

References (11)

1. Fareed J, Kumar A, Walenga JM, Emanuele RM, Williamson K, Hoppensteadt D. Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv Rev Fr Hematol 1984;26:267.
2. Fareed J, Walenga JM, Racanelli A, Hoppensteadt D, Huan X, Messmore HL. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Haemostasis 1988; 18(Suppl 3):33.
3. Barrett JS, Hainer JW, Kornhauser DM, et al. Anti-coagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers. Thromb Res 2001;101:243.
4. Fareed J, Haas S, Sasahara A, eds. Differentiation of low molecular weight heparins. Applied and clinical considerations. Semin Thromb Hemost 1999;25(3):17.
5. Fareed J, Walenga JM, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Haemostasis 1988;18(Suppl 3):3.
6. Fareed J, Walenga JM, Williamson K, Emanuele RM, Kumar A, Hoppensteadt D. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Semin Thromb Hemost 1985;11(1):56.
7. Memorandum on a provisional International Standard for heparin. Bull WHO 1942;151.
8. Barrowcliffe TW, Curtiss AD, Johnson EA, Thomas DP. An internatiuonal standard for low molecular weight heparin. Thromb Haemost 1988;60:1.
9. Mulloy B, Gee C, Wheeler SF, Wait R, Gray E, Barrowcliffe TW. Molecular weight measurements of low molecular weight heparins by gel permeation chromatography. Thromb Haemost 1997;77(4):668.
10. Cambus JP, Saivin S, Heilmann JJ, Caplain H, Boneu B, Houin G. The pharmacodynamics of tinzaparin in healthy volunteers. Br J Hematol 2002;116:649.
11. The Wall Street Journal. Thursday June 12, 2003. Page A3, Vol. CCXLI 114. Bush Acts to Speed Generics to Market (Leila Abboud).